Our Commitment

TERAVOLT is committed to understanding the impact of COVID-19 on thoracic malignancies. Specifically, we aim to:

  • Understand risk factors associated with morbidity and mortality in patients with thoracic malignancies who are infected with COVID-19
  • Determine therapies that may impact survival in patients with thoracic malignancies who are infected with COVID-19
  • Provide collaborators and the global medical community with guidance on the management of patients with thoracic malignancies during the COVID-19 pandemic